Project Grant HT94252410656
Award Date
6/1/24
Completion Date
5/31/27
Dollars Obligated
$1.4M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Irvine, CA 92697, USA
Similar Awards
The University of California Irvine (UC Irvine) was awarded a $513,084.00 Project Grant by the Defense Health Agency under the Department of Defense's Military Medical Research and Development program (CFDA 12.420). The grant, titled "Intravital Imaging of Melanoma Tumors for Mechanism Discovery and Patient Surveillance After Checkpoint Blockade", will fund research to investigate innovative imaging techniques for studying melanoma tumors and monitoring patient response to...
The University of California, Davis was awarded a $1,446,009 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) to target CD200/CD200R signaling as a novel strategy for treating therapy-resistant prostate cancer. The grant, awarded July 1, 2023 and set to be completed by June 30, 2026, will support research into medical solutions for prostate cancer that remains unresponsive to standard treatments by...
The University of California, Los Angeles (UCLA) has been awarded a $626,081 Project Grant under the Military Medical Research and Development (CFDA 12.420) federal grant program, administered by the Defense Health Agency. The grant, titled "Combinatorial Phenotype-Targeted Therapy to Overcome Mechanisms Driving Prostate Cancer Treatment Resistance," will support advanced biomedical research to transform healthcare for military service members and the broader public. The research...
This Project Grant award of $636,285 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the University of California, Davis (UC Davis) on "TRIPLE AKR1C3/COX2/SEH INHIBITION FOR THE TREATMENT OF LETHAL PROSTATE CANCER." The funding will be used over a 3-year period from September 2023 to August 2026 to conduct basic, translational, and clinical research aimed at developing new treatments for prostate cancer, a key health...
The University of California, Davis was awarded a $1,446,250 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) to conduct research on "THERAPEUTIC TARGETING OF A NOVEL TUMOR-INTRINSIC SIGNALING PATHWAY FOR LETHAL PROSTATE CANCER." The award period is from August 1, 2023 to July 31, 2026. UC Davis will leverage its expertise in medical research to investigate potential medical solutions relevant to the...
The University of California, Los Angeles will receive $2.34 million under a Project Grant award from the Department of the Army Medical Command to target N-cadherin for inhibition of enzalutamide resistance and emergence of neuroendocrine prostate cancer. The grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve military and public health through innovative medical solutions for battlefield care and other...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $523,266 project grant to the University of California Irvine. The 3-year grant, awarded on Sep 15, 2023, will support intravital imaging research on melanoma tumors to improve understanding of the mechanisms of action and patient surveillance for checkpoint blockade immunotherapy. The project aims to leverage UC Irvine's research capabilities and specialized facilities in biomedical...
The Defense Health Agency awarded a $468,000 Project Grant to the University of California, Los Angeles under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research developing new therapeutic strategies to target TROP2 in aggressive prostate cancer. The two-year award beginning March 15, 2023 will fund research efforts to investigate medical solutions for prostate cancer on the battlefield and transform health care for service members and the public...
This Project Grant award for $810,472, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research at the University of California, Davis aimed at the development of a triple inhibitor treatment for lethal prostate cancer. The research is focused on simultaneously inhibiting the AKR1C3, COX2, and SEH enzymes, which play key roles in the progression of aggressive forms of prostate cancer. The award has a performance period...
The University of California, San Diego (UCSD) was awarded a $1,218,012 Project Grant from the Defense Health Agency on September 30, 2023 under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "GERMLINE INFLUENCE ON PROSTATE CANCER METASTASIS AND TREATMENT RESPONSE." The research aims to transform health care for Service Members and the American public by investigating medical solutions for the battlefield through innovative and impactful...